MIT's Dane Wittrup, one of the scientific founders behind Eleven Biotherapeutics, says he and a trio of grad students have developed some significant new insights into amping up the performance of cancer immunotherapies.
Zeroing in on an enzyme that is over-expressed in brain tumor cells, two investigators at Houston Methodist say they have developed a new treatment for gliomas that has cleared its preclinical testing and should be ready for human testing within the next one to two years. Read more >>
Psoriasis has attracted a big pack of rival drug giants anxious to be in the lead with a new wave of better, targeted therapies for legions of patients. But a team of investigators at Rockefeller University say they just scored early-stage data on a new drug from Boehringer Ingelheim that promises to offer a potential cure with a more durable therapy. Read more >>
POPULAR COMMENT THREADS
Armed with NIH funding, a group of investigators at the University of Chicago Medical Center have been studying the positive effects of an ancient Chinese remedy derived from magnolia tree bark, which may have potential in guarding against heart disease.
Nicotine addiction has already defeated a number of companies that have tried to come up with an effective cure. Now scientists at the University of Massachusetts Medical School and The Scripps Research Institute say they have identified a particular circuit in the brain that promotes anxiety during withdrawal--offering a new approach in R&D.
Preclinical research can play a big role in pursuing new combination therapies. Case in point: Infinity's duvelisib (IPI-145). Partnered with AbbVie, investigators have gone back to the lab to help establish what the PI3K-delta/gamma inhibitor might best be paired with. And not too surprisingly they concluded that AbbVie's BCL-2 protein inhibitor venetoclax (ABT-199) might make a good match.
What's the next step for researchers focused on PD-1 and PD-L1, the two big targets for checkpoint inhibitors that are now hitting the oncology market? Scientists at The University of Texas MD Anderson Cancer Center offered one potential pathway, pointing to the role of p53 in spurring the advance of non-small cell lung cancer. And they're now working on an experimental lung cancer drug that has shown promise in a mouse study.
Building on insights that antibodies generated by lupus can also kill cancer cells, investigators at Yale School of Medicine say that they have found a way to engineer these antibodies into a more efficient weapon.
Investigators believe that they have found a new approach to treating HER2-positive breast cancer in a class of enzymes called protein tyrosine phosphatases, or PTPs, which plays a role in cell proliferation.
From Our Sister Sites
Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.
Veracyte is selling $40 million of its common stock in a private placement to generate some cash for R&D, adding fuel to its engine as it inks new deals and looks to expand its portfolio.